Table 1.
Glucose-lowering drug regimens of patients in both groups before and after propensity-score matching.
| Glucose-Lowering Drugs | Unmatched | Propensity-Score Matched | ||||
|---|---|---|---|---|---|---|
| SGLT-2 Inhibitors (n = 38) |
Non-SGLT-2 Inhibitors (n = 66) |
p-Value | SGLT-2 Inhibitors (n = 38) |
Non-SGLT-2 Inhibitors (n = 38) |
p-Value | |
| Metformin | 35 (92%) | 34 (52%) | <0.001 | 35 (92%) | 31 (82%) | 0.309 |
| Dipeptidyl peptidase 4 inhibitors | 8 (21%) | 18 (27%) | 0.638 | 8 (21%) | 8 (21%) | 1 |
| Sulfonylurea | 2 (5%) | 3 (5%) | 1 | 2 (5%) | 2 (5%) | 1 |
| Insulin | 9 (24%) | 21 (32%) | 0.511 | 9 (24%) | 7 (18%) | 0.778 |
| Sodium-glucose cotransporter 2 inhibitors | 38 (100%) | 0 | – | 38 (100%) | 0 | – |
| Glucagon-like peptide 1 receptor agonist | 3 (8%) | 1 (2%) | 0.271 | 3 (8%) | 1 (3%) | 0.615 |
SGLT-2: sodium-glucose cotransporter-2; “–“: not applicable.